Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Other Operating Expenses (2019 - 2025)

Historic Other Operating Expenses for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $29.5 million.

  • Harmony Biosciences Holdings' Other Operating Expenses rose 715.48% to $29.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.9 million, marking a year-over-year increase of 701.53%. This contributed to the annual value of $110.9 million for FY2024, which is 1387.21% up from last year.
  • As of Q3 2025, Harmony Biosciences Holdings' Other Operating Expenses stood at $29.5 million, which was up 715.48% from $30.1 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Other Operating Expenses registered a high of $30.7 million during Q1 2025, and its lowest value of $15.5 million during Q1 2021.
  • Its 5-year average for Other Operating Expenses is $23.5 million, with a median of $23.4 million in 2023.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first surged by 3679.98% in 2021, then soared by 265.57% in 2024.
  • Harmony Biosciences Holdings' Other Operating Expenses (Quarter) stood at $19.1 million in 2021, then grew by 10.29% to $21.1 million in 2022, then increased by 27.57% to $26.9 million in 2023, then rose by 2.66% to $27.6 million in 2024, then grew by 7.06% to $29.5 million in 2025.
  • Its Other Operating Expenses stands at $29.5 million for Q3 2025, versus $30.1 million for Q2 2025 and $30.7 million for Q1 2025.